Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

January 25, 2024

https://www.globenewswire.com/news-release/2024/01/25/2816523/0/en/Vera-Therapeutics-Presents-Positive-72-Week-Data-Showing-eGFR-Stabilization-in-the-Phase-2b-ORIGIN-Clinical-Trial-OLE-in-IgA-Nephropathy.html

– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment

Read more at globenewswire.com

Related news for (VERA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.